International registry of spinal dural arteriovenous fistula outcomes
SPIDER - Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry
This registry will collect treatment and outcome data from people with spinal dural arteriovenous fistulas to see which treatments and factors relate to recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT07574645 on ClinicalTrials.gov |
What this trial studies
Type 1 spinal dural arteriovenous fistulas (SDAVFs) are a rare but important cause of progressive myelopathy that are often underdiagnosed and variably treated. This international, multicenter registry pools de-identified patient-level data from contributing centers to create a large dataset of surgically or endovascularly treated SDAVF cases with at least one primary outcome recorded. Researchers will use standardized clinical scales and harmonized variables to analyze diagnostic delays, treatment strategies (endovascular, surgical, or combined), recurrence rates, and predictors of functional outcome. The registry is designed to provide more generalizable evidence than single-center series and to inform clinical decision-making and benchmarking across institutions.
Who should consider this trial
Good fit: Ideal candidates are people with imaging-confirmed type 1 spinal dural arteriovenous fistulas who have undergone surgical or endovascular treatment and have at least one recorded primary outcome.
Not a fit: Patients with other types of spinal vascular malformations, untreated SDAVFs, or no available outcome data are unlikely to be included or to directly benefit from participation.
Why it matters
Potential benefit: If successful, this registry could clarify which treatments and care pathways lead to better long-term function and faster diagnosis for people with SDAVF.
How similar studies have performed: Previous evidence has relied on single-center retrospective series, so while registries in other rare vascular conditions have been informative, a large international SDAVF registry of this scope is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 1 spinal dural arteriovenous fistula, confirmed on imaging * Surgically or endovascularly treated * At least 1 available primary outcome
Where this trial is running
Philadelphia, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Pascal Jabbour, MD
- Email: pascal.jabbour@jefferson.edu
- Phone: 215-955-7000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.